#United States #San Diego #Robbins LLP #REGENXBIO #RGNX

Class Action Lawsuit Against REGENXBIO Increasingly Heats Up

In recent developments that have alarmed investors, Robbins LLP has launched a class action lawsuit on behalf of shareholders of REGENXBIO, Inc. (NASDAQ: RGNX). This legal action comes after revelations regarding serious safety problems related to one of its leading gene therapy candidates, RGX-111. The claim has been filed for those who bought or acquired REGENXBIO stocks between February 9, 2022, and January 27, 2026.

Background of REGENXBIO, Inc.

REGENXBIO is a prominent clinical-stage biotechnology company that specializes in innovative gene therapies aimed at treating genetic defects. The firm has made headlines for its proprietary NAV AAVP vector technology, designed to deliver functional genes directly into cells. Despite the company's optimistic portrayals regarding the drug RGX-111, the recent disturbances stemming from safety allegations have cast a shadow over its reputation.

The Allegations

According to the lawsuit, REGENXBIO allegedly misled investors about the safety and effectiveness of RGX-111, which was primarily developed for treating Mucopolysaccharidosis Type I (MPS I). The lawsuit accuses the company of consistently suggesting that clinical trials were producing favorable results while being aware of severe safety risks. Allegations point to critical issues that, if not disclosed, were detrimental to investors.

The complaint highlights that in 2018, the FDA had granted RGX-111 Fast Track designation, generating widespread confidence among shareholders. Robbins LLP claims that although REGENXBIO touted positive results from clinical tests, it concealed the fact that significant safety concerns, including the potential for central nervous system tumors, persisted. Moreover, it alleged that the company made abrupt changes in strategy regarding RGX-111, further impacting investor trust.

The crisis escalated when the FDA enforced a clinical hold on RGX-111 due to an investigation related to one case of a CNS tumor identified in trial participants. Consequently, shares of REGENXBIO plummeted from a closing price of $13.41 to $11.01 in a single day—a staggering 17.8% decline.

What Should Shareholders Do?

For those affected, it is crucial to act quickly; the deadline for becoming a lead plaintiff in the class action lawsuit is April 14, 2026. Being a lead plaintiff means representing your fellow shareholders in the ongoing litigation. However, shareholders are not required to engage actively to be eligible for any potential recovery.

The attorneys at Robbins LLP work on a contingency fee basis, implying that shareholders incur no costs unless the case is won. Thus, pursuing this legal route could recover losses without financial risk at the outset.

How to Seek Help

Shareholders wishing to obtain further information or participate in this class action can contact attorney Aaron Dumas, Jr. at Robbins LLP or call (800) 350-6003. Investors are encouraged to stay informed, especially since significant updates can manifest quickly, influencing their legal standing and financial position.

About Robbins LLP

Since its establishment in 2002, Robbins LLP has become a recognized leader in shareholder rights litigation. The firm is committed to assisting investors in reclaiming losses and enhancing corporate governance. Their seasoned legal team is well-versed in handling complex litigation surrounding deceptive corporate practices.

Investors must engage actively and ensure their voices are heard as they navigate through this complex legal landscape. Staying informed about the status of the lawsuit can prove critical in determining the outcomes for REGENXBIO shareholders going forward.